Infinity Inks Deal With Roche for Phase II Study of IPI-549

Shares of Infinity Pharmaceuticals Inc. INFI rose almost 24% after the company announced that it has entered into a master clinical supply agreement with Roche RHHBY. Per the deal, Roche will supply Tecentriq (atezolizumab) to Infinity for use in MARIO-3, a phase II multi-arm combination cohort study. The study will evaluate Infinity’s lead immuno-oncology candidate, IPI-549in combination with Tecentriq and Abraxane (nab-paclitaxel) in front-line triple negative breast cancer (TNBC), and IPI-549 in combinat...

Infinity Pharmaceuticals beats by $0.03, revenue in-line - Infinity Pharmaceuticals, Inc. (NASDAQ:INFI)

Infinity Pharmaceuticals Reports Full Year 2018 Financial Results and Provides Company Update

CAMBRIDGE, Mass., March 14, 2019 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its full year 2018 financial results and provided an update on the company, including its progress with IPI-549, a first-in-class oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through selective phosphoinositide-3-kinase-gamma (PI3K-gamma) inhibition. Today, Infinity also announced MARIO-3, a Phase 2 study in collaboration with Roche, which will e...